Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Inclusion Criteria: * A histologic diagnosis of primary peritoneal carcinoma or epithelial ovarian carcinoma, Stage III - IV, expressing the tumor-associated antigen CA125 as measured by a serum CA125 level ≥ 35 U/mL and tumor tissue which has been demonstrated by immunohistochemical methods to express CA125. All patients must provide primary tumor (and lymph node and ascites samples, if available) samples for cellular immunology assays and characterization * A functional performance status of ≤2 on the ECOG scale * Are randomized into the study no more than eight (8) weeks postoperatively * Have an expected survival of at least 6 months * Age less than or equal to 80 years of age * Be willing and able to comply with the protocol for the duration of the study * Have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care Exclusion Criteria: * Have received radiotherapy or chemotherapy * Have circumstances at the time of entry onto the protocol would not permit completion of study or require follow-up * Have other invasive malignancies, with the exception of non-melanoma skin cancer and carcinoma in situ of the cervix, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy * Have significant cardiovascula…